SCHEMBL3572103

SCHEMBL3572103

N#Cc1cnc2oc(-c3ccccc3)c(-c3ccccc3)c2c1NCCN1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 3/20 0.52
HPGD P15428 3/20 0.52
HSD17B10 Q99714 3/20 0.52
NPSR1 Q6W5P4 2/20 0.52
USP2 O75604 2/20 0.52
TSHR P16473 2/20 0.52
MAPK1 P28482 2/20 0.52
AURKA O14965 1/20 0.52
HTT P42858 1/20 0.52
LCK P06239 16/20 0.52
TNK2 Q07912 16/20 0.52
KDR P35968 9/20 0.52
JAK3 P52333 8/20 0.52
EGFR P00533 2/20 0.49
SRC P12931 2/20 0.49
ZAP70 P43403 2/20 0.49
ALOX12 P18054 1/20 0.48
MAPT P10636 1/20 0.46
JAK2 O60674 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3566479 0.99 KDM4E (0.53) KDM4EALDH1A1HPGDHSD17B10NPSR1
SCHEMBL3572129 0.91 LCK (0.65) KDM4EALDH1A1HPGDHSD17B10NPSR1
SCHEMBL3568195 0.91 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10NPSR1
SCHEMBL3565187 0.87 LCK (0.70) LCKTNK2KDRJAK3EGFR
SCHEMBL5255430 0.84 LCK (0.45) KDM4EALDH1A1HPGDHSD17B10NPSR1
SCHEMBL3573895 0.82 HRH2 (0.43) KDM4EALDH1A1HPGDHSD17B10NPSR1
SCHEMBL3566434 0.81 ALDH1A1 (0.58) KDM4EALDH1A1HPGDHSD17B10NPSR1
SCHEMBL3561428 0.81 TNK2 (0.52) LCKTNK2KDRJAK3EGFR
SCHEMBL3563328 0.81 AURKA (0.51) KDM4EALDH1A1HPGDHSD17B10NPSR1
SCHEMBL5253928 0.81 LCK (0.45) KDM4EALDH1A1HPGDHSD17B10NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US claimed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US claimed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 KDM4E 2251/4885ALDH1A1 869/4885HPGD 2117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.